NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/19/2023
Back to search
Official data from USPTO
BOMYNTRA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
12
Latest update
12/19/2023
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
03/07/2023
Registration date
12/19/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/19/2023
Last transaction
12/19/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
16
Owner location
Bad Homburg, DE
Examiner
NODES, CHRISTOPHER
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Fresenius Kabi Deutschland GmbH
Representatives
SCOTT D. WOLDOW SMITH, GAMBRELL & RUSSELL, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use for the treatment of oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for the prevention of fractures; pharmaceutical preparations for human use for prevention of pain associated with oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for surgeryfor prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for radiotherapyfor prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for the treatment and prevention of bone metastasessolid tumorsosteolytic bone lesions of multiple myelomahypercalcemia of malignancygiant cell tumor of bone
Publications
History of USPTO decisions and trademark events.
12 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/19/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/03/2023
PUBO
PUBLISHED FOR OPPOSITION
10/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/13/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/24/2023
DOCK
ASSIGNED TO EXAMINER
08/21/2023
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
07/28/2023
ALIE
ASSIGNED TO LIE
07/28/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/27/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/21/2023
NWAP
NEW APPLICATION ENTERED
03/10/2023
Continuous trademark protection
Get notified about every new filing that threatens BOMYNTRA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.